FDA Clears Teplizumab for Kids Newly Diagnosed With Type 1 Diabetes
The FDA has widened its approval of teplizumab to children and teens ages 8 to 17 who were just diagnosed with stage 3 type 1 diabetes, giving families a shot at slowing the immune attack on their insulin-making cells. Trial data shows most treated kids held onto meaningful insulin production. The catch: treatment has to start within eight weeks.
- Original source: scitechdaily.com.
- The source published it on Nov 17, 2026 at 4:07 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
In June 2026, the FDA expanded teplizumab's label to cover children and adolescents ages 8 to 17 with newly diagnosed stage 3 type 1 diabetes — the stage where symptoms show up and insulin shots become unavoidable. The green light came through the agency's accelerated approval pathway, based on evidence the drug protects insulin production. Teplizumab was already cleared for people ages 1 and older with stage 2 disease, where it's used to stall the slide into stage 3.
Type 1 diabetes kicks in when the immune system attacks the pancreas's beta cells, the ones that make insulin. By the time symptoms appear, some of those cells are usually still standing. In the PROTECT trial, which enrolled 328 children and adolescents, participants on teplizumab kept significantly more insulin-producing capacity after 78 weeks than those on placebo, measured through C-peptide, a marker of the body's own insulin output. Nearly 95% of treated kids held a clinically meaningful level of their own insulin production, versus about 79% on placebo. Separate studies have tied higher C-peptide levels to fewer severe low blood sugar episodes, lower insulin needs and a reduced risk of complications including diabetic eye disease.
Timing is everything. Teplizumab must begin within eight weeks of diagnosis, and PROTECT participants started inside six weeks — earlier research hints that faster starts get stronger responses. The regimen is two 12-day courses of daily intravenous infusions, usually about six months apart. Possible side effects include rash, headache, nausea and temporary dips in lymphocytes, a type of white blood cell. The serious list — cytokine release syndrome, infections and viral reactivation — means experienced medical teams and close monitoring are non-negotiable. The drug doesn't cure type 1 diabetes or erase the need for insulin; it takes aim at the immune process doing the damage.
Kimber Simmons, MD, MS, an associate professor of pediatrics at the University of Colorado Anschutz School of Medicine and a physician-scientist at the Barbara Davis Center for Diabetes, led a national group of trial investigators and pediatric diabetes specialists in writing practical guidance published in Diabetes Care on 11 November 2026. Backed by Breakthrough T1D, it walks clinicians through patient selection, benefits and risks, shared decision-making, safety monitoring and treatment planning. Simmons, who also practices at Children's Hospital Colorado, co-authored the published results of both PROTECT and PETITE-T1D, a study of teplizumab in children under 8 with stage 2 disease. I'm not going to reproduce a fake quote.
TopicsFDA · teplizumab · PROTECT trial · Kimber Simmons · Breakthrough T1D · University of Colorado Anschutz School of Medicine · Diabetes Care · Anastasia Albanese-O'Neill
Source: scitechdaily.com
Written by AI from verified reporting.
More stories
- Health & science medicalxpress.com Caught by @lantern129 0 viewsRNA dimmer switch helps mice survive lethal sepsis, study finds
- Health & science inquirer.com Caught by @Midas👑 0 viewsCDC Study Finds 112 Pregnant Women and 13 Newborns Sickened by Measles
- Health & science theguardian.com 0 viewsEuropean Pesticides Named in 1,605 Brazil Poisoning Reports
- Health & science theepochtimes.com 0 viewsFDA Refuses to Approve Akeso-Summit Lung Cancer Drug After Survival Miss

